Question:rso And Blood Pressure

[Rx420]

I am confused about a treatment issue.  I have heard RSO will lower blood pressure and one should be cautious.  I am trying to lower my blood pressure, but it's not clear if the RSO treatment to lower Blood pressure involves a massive intake of RSO, similar to the 60 gram cancer program, or a continuous and on going maintenance does of a dab a day?   

 

The "Massive Dose Theory" presumes one consumes a massive does in order to "reset" the bp long term....The "Dab a Day Theory" presumes one cannot "reset" the blood pressure long term using a cannabis therapy, but that such therapies can be effective in "controlling" bp if the oil is taken in small daily doses. 

 

Anyone have any experience or thoughts?  Thanks 

[cristinew]

http://circ.ahajourn...10/14/1996.full

 

 

 

• Hypertension

Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension

1. Sándor Bátkai, MD, PhD*; 
2. Pál Pacher, MD, PhD*; 
3. Douglas Osei-Hyiaman, MD, PhD; 
4. Svetlana Radaeva, PhD; 
5. Jie Liu, MD, PhD; 
6. Judith Harvey-White, MSc; 
7. László Offertáler, MD; 
8. Ken Mackie, MD; 
9. M. Audrey Rudd, PhD;
10. Richard D. Bukoski, PhD; 
11. George Kunos, MD, PhD
12.  
13.  
14. A good read on why it should be part of the treatment ,,

 

Background— Endocannabinoids are novel lipid mediators with hypotensive and cardiodepressor activity. Here, we examined the possible role of the endocannabinergic system in cardiovascular regulation in hypertension.

Methods and Results— In spontaneously hypertensive rats (SHR), cannabinoid-1 receptor (CB₁) antagonists increase blood pressure and left ventricular contractile performance. Conversely, preventing the degradation of the endocannabinoid anandamide by an inhibitor of fatty acid amidohydrolase reduces blood pressure, cardiac contractility, and vascular resistance to levels in normotensive rats, and these effects are prevented by CB₁ antagonists. Similar changes are observed in 2 additional models of hypertension, whereas in normotensive control rats, the same parameters remain unaffected by any of these treatments. CB₁ agonists lower blood pressuremuch more in SHR than in normotensive Wistar-Kyoto rats, and the expression of CB₁ is increased in heart and aortic endothelium of SHR compared with Wistar-Kyoto rats.

Conclusions— We conclude that endocannabinoids tonically suppress cardiac contractility in hypertension and that enhancing the CB₁-mediated cardiodepressor and vasodilator effects of endogenous anandamide by blocking its hydrolysis can normalize blood pressure. Targeting the endocannabinoid system offers novel therapeutic strategies in the treatment of hypertension.

[Rx420]

THANK YOU!